Wegovy labeling adds single-dose syringes in five strengths

Wegovy's (semaglutide) FDA-approved labeling now lists a single-dose syringe among the forms the once-weekly injection comes in, at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg strengths ^[2]. The same labeling lists single-dose pens in those five strengths, plus a higher-dose 7.2 mg pen (Wegovy HD) and a 9.6 mg/3 mL pen that delivers four 2.4 mg doses ^[2].

The new device joins the pen and the once-daily Wegovy pill, which the labeling lists at 1.5 mg, 4 mg, 9 mg, and 25 mg ^[2]. Wegovy has been available in pen form since 2021 ^[1]. Novo Nordisk's consumer information page describes the pen as a prefilled, single-use device with a hidden needle that is preset with the prescribed dose, and describes the pill as the other way to take the medicine; it does not mention a syringe ^[1].

How the injection is used

Wegovy injection is given once weekly, on the same day each week, at any time of day, with or without meals, into the abdomen, thigh, or upper arm ^[2]. Treatment starts at 0.25 mg once weekly for four weeks and then moves up on a schedule that titrates every four weeks, with 2.4 mg once weekly as the usual maintenance dose ^[2]. The five syringe strengths line up with that schedule from the starting dose through the standard maintenance dose ^[2].

When the syringes will arrive in pharmacies, what they will cost, and whether insurers will cover them on the same terms as the pen have not been reported. Whether patients will be able to move between the pen and the syringe without a new prescription has also not been reported.

Why it matters for patients

Semaglutide is the same active ingredient in either device, and the weekly schedule is the same. What changes is how the medicine gets into the body. The pen hides its needle and is preset to the prescribed dose ^[1]. The syringe is a separate single-dose device that is handled differently, so the instructions a patient follows at home change even though the drug does not ^[1][2].

Injectable GLP-1 medicines carry a boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and it is not known whether Wegovy causes these tumors, including medullary thyroid carcinoma, in humans. Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[2]. Those warnings apply to both devices.

The most common side effects, seen in at least 5% of patients, include nausea, diarrhea, vomiting, constipation, abdominal pain, changes in skin sensation, headache, fatigue, indigestion, dizziness, bloating, belching, flatulence, gastroenteritis, reflux, hair loss, and low blood sugar in people with type 2 diabetes ^[2]. The labeling also warns patients never to share the FlexTouch pen with another person, even if the needle is changed ^[2]. A single-dose syringe is designed for one use by one person.

Insurance coverage rules for GLP-1 obesity drugs have often been tied to the specific product a pharmacy dispenses, so a new device format can raise questions about copays and prior authorizations. Whether that happens with the syringe has not been reported, and no cost information has been disclosed.

What happens next

Wegovy's prescribing information was most recently revised in June 2026, and its dosage and administration sections carry update dates of August 2025, December 2025, and March 2026 ^[2]. A launch date for the syringe, a pharmacy availability timeline, and pricing have not been reported.

Separately, Novo Nordisk's consumer page warns that compounded or knockoff semaglutide has not been approved by the FDA and has not been proven safe or effective, and states that semaglutide medicines not made by Novo Nordisk are not FDA-approved semaglutide ^[1].